Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-08 · accession 0000950170-25-052310 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-09 | 2025-04-08 | KYMR | Goodman Noah | Chief Business Off | A - Grant | $0.00 | +50.0K | 50.1K | +61,395% | $0 |
| D | 2025-04-09 | 2025-04-08 | KYMR | Goodman Noah | Chief Business Off | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-08 | A | A | 50,000 | $0.00 | 50,081.44 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following April 8, 2025, subject to the reporting person's continued employment through each vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-04-08 | A | A | 100,000 | $0.00 | 100,000 | D | $21.05 · — to 2035-04-07 | 100,000 Common Stock | (F2) Twenty-five percent (25%) of the shares underlying this stock option shall vest on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. |